Celgene and bluebird bio announce updated results from ongoing multicenter phase 1 study
Celgene and bluebird bio announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma. December 10, 2017